ANIP vs AZN: fair value comparison
ANI Pharmaceuticals, Inc. and AstraZeneca PLC · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AZN currently sits closer to the top of our discount ranking. ANIP carries the stronger quality grade.
| ANIP | AZN | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $71.92 | $162.47 |
| 12-month range | $71.92–$94.06 | $156.93–$202.39 |
| Sector rank | #11 of 113 Healthcare | #5 of 113 Healthcare |
| Quality grade | A | C |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: ANIP fair value analysis · AZN fair value analysis